LabCompass

Joseph Stanek

Medicine · The Ohio State University

Established · publishing since 1970

Publications

270

Citations

2,296

Est. group size

~22

Recurring co-author estimate

Active years

56

Publishing since 1970

Research summary
AI-generated

Joseph Stanek's work focuses on pediatric hematology and oncology, particularly sickle cell disease, blood clotting disorders, and childhood cancer care. Recent studies examine complications and health outcomes in young patients, including reproductive health, vaccine uptake, thromboembolism, and survivorship issues after cancer treatment or stem cell transplantation. Much of this research combines clinical outcomes data with efforts to improve screening, education, and long-term care for children and adolescents with blood disorders and cancer.

Sickle cell disease in children and adolescentsPediatric blood clotting (thrombosis) disordersChildhood cancer survivorship and long-term outcomesHematopoietic stem cell transplantation complicationsAdolescent reproductive and preventive health

Publication output has remained fairly steady over the past decade, rising from 17 in 2017 to a peak of 39 in 2022, with a slight decline in the most recent years (2023-2025).

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 23.4/year recently
2017: 17 publications172018: 37 publications182019: 20 publications192020: 28 publications202021: 31 publications212022: 39 publications39222023: 30 publications232024: 27 publications242025: 21 publications2526
Recent publications
Publishes in
  • Neuro-Oncology×36
  • Pediatric Blood & Cancer×30
  • Blood×28
  • Biology of Blood and Marrow Transplantation×17
  • Journal of Pediatric Hematology/Oncology×10
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 19, 2026.

Claim or correct this profile